Funding for this research was provided by:
AACR-TNBC Foundation Grant (15-20-43)
Scariot Foundation (NA)
Received: 18 August 2020
Accepted: 18 February 2021
First Online: 4 March 2021
Ethics approval and consent to participate
: The study was reviewed and approved by the UAB Institutional Review Board.
: The manuscript contains images of an individual. Consent was obtained and available upon request.
: E. Yang: consultant for AstraZeneca; advisory board for Clovis Oncology, Strata Oncology, Bayer, and Lilly; research funding from Tesaro/Janssen.E. Stringer-Reasor: involved in clinical trials with money paid directly to UAB from Seattle Genetics, Pfizer, Novartis, TESARO, and GSK; on advisory boards for Mylan Institutional and Lilly; grants provided by Susan G. Komen and Victory Foundation.C. Falkson: advisory boards for Agendia, Biotheranostics, and Oncotype Dx.G. Rocque: grants from Genetech, Pfizer, and Carevive; consult for Pfizer.C. Vaklavas: consulting/advisory role: Daiichi-Sankyo (one time); research funding paid to my institution: Seattle Genetics, Genentech, Roche, Pfizer, Incyte, Pharmacyclics, Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks, and H3 Biomedicine; other relationships: Puma Biotechnology, Takeda, Daiichi Sankyo; uncompensated relationship: Genentech (unpaid thought leader).E. Acosta, L, Yufeng, L. Nabell, J. May, E. Olariu, D. Della Manna, and V. Caterinicchia have no conflicts to disclose.